Drugs Made In America Acquisition II Corp. Ordinary Shares
DMII | NASDAQ
$10.20
$0.00 (0.00%)
At close: Oct 30, 2026, 3:59 PM ET
$10.19
-$0.01 (-0.10%)
After-hours:
Oct 30, 2026, 4:02 PM ET
Fiscal Quarter Period Ending | Q2 2026 Jun 30, 2026 | Q1 2026 Mar 31, 2026 | Q4 2025 Dec 31, 2025 | Q3 2025 Sep 30, 2025 |
|---|---|---|---|---|
Net Income | 4.4M | 4.34M | 4.33M | -46.16K |
Depreciation & Amortization | n/a | n/a | n/a | n/a |
Stock-Based Compensation | n/a | n/a | n/a | n/a |
Other Working Capital | -38.81K | -473 | -174.16K | -2.15K |
Other Non-Cash Items | -4.53M | -4.47M | -4.47M | -78.75K |
Deferred Income Tax | n/a | n/a | n/a | n/a |
Change in Working Capital | -38.81K | 29.53K | -174.16K | -565.82K |
Operating Cash Flow | -172.75K | -102.5K | -314.86K | -690.73K |
Capital Expenditures | n/a | n/a | n/a | -4 |
Cash Acquisitions | n/a | n/a | n/a | n/a |
Purchase of Investments | n/a | n/a | n/a | -500M |
Sales Maturities Of Investments | n/a | n/a | n/a | n/a |
Other Investing Acitivies | n/a | n/a | n/a | n/a |
Investing Cash Flow | n/a | n/a | n/a | -500M |
Debt Repayment | n/a | 450K | n/a | -533.78K |
Common Stock Repurchased | n/a | n/a | n/a | n/a |
Dividend Paid | n/a | n/a | n/a | n/a |
Other Financial Acitivies | n/a | n/a | n/a | -464.8K |
Financial Cash Flow | n/a | 450K | n/a | 501M |
Net Cash Flow | -172.75K | 347.5K | -314.86K | 310.69K |
Free Cash Flow | -172.75K | -102.5K | -314.86K | -690.73K |
Adj. Free Cash Flow | -172.75K | -102.5K | -314.86K | -690.73K |
Maintenance CapEx | n/a | n/a | n/a | n/a |
Growth CapEx | n/a | n/a | n/a | -4 |
Owner Earnings | -172.75K | -102.5K | -314.86K | -690.73K |
Add to Watchlist
Select watchlists to add or remove DMII